Select Page

Cancer Drug Pipeline Information for Patient Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained on this website is not a comprehensive list. While we make reasonable efforts to present current and accurate information on this website, this website could include inaccuracies or typographical errors. We do not guarantee and are not responsible for the quality, currency, propriety, accuracy, or reasonableness of any information on this website. Please contact info@canceraction.ca with any inquiries about the terms of use.

Brand NameGeneric NameManufacturerTumour SiteIndicationRoute of AdministrationInformation Source
MasivetmasitinibAB ScienceGastrointestinalRelapsed metastatic colorectal cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalMetastatic pancreatic cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, first-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceMelanomaMetastatic melanoma with JM mutation of c-KITOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, second-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGynecologyRelapsed advanced / metastatic epithelial ovarian cancer patients in second line refractory to first line platinum treatment or in third lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGenitourinaryMetastatic Castrate Resistant Prostate Cancer in first lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceLymphomaRelapsed or refractory peripheral T-cell lymphomaOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
VenclextavenetoclaxAbbVieLeukemiaChronic lymphocytic leukemia (CLL), relapsed-refractory and first lineOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaFollicular Lymphoma (FL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaDiffuse Large B-Cell Lymphoma (DLBCL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
veliparibAbbVieLungOvarian cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieBreastBreast cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieLungLung cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, third lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, first lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer,second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieGastrointestinalPancreatic cancerOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLeukemiaAcute myeloid leukemia (AML)Oral
ImbruvicaibrutinibAbbVieMyelomaMultiple myelomaOral
ImbruvicaibrutinibAbbVieLymphomaMarginal zone lymphoma (MZL), relapsed/refractoryOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaDiffuse large B-cell lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaFollicular lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma treatment naïveIntravenoushttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
depatuxizumab mafodotinAbbVieNeurologicalGlioblastoma MultiformeIntravenoushttps://www.abbvie.com/our-science/pipeline/depatuxizumab-mafodotin.html
Imlygictalimogene laherparepvecAmgenMelanomaUnresected metastatic melanomaSubcutaneoushttp://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=talimogene+laherparepvec
VectibixpanitumumabAmgenGastrointestinalChemorefractory, wild-type KRAS exon 2 metastatic colorectal cancerIntravenous
XgevadenosumabAmgenOtherAdults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbiditySubcutaneoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
KyproliscarfilzomibAmgenMyelomaMultiple myeloma, in combination with chemotherapyIntravenoushttp://www.amgenpipeline.com/pipeline/
KyproliscarfilzomibAmgenLungSmall-cell lung cancerIntravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLeukemiaPhiladelphia Positive/BCR-ABL Positive Acute Lymphoblastic LeukemiaIntravenoushttp://www.amgenpipeline.com/pipeline/
IclusigponatinibAriad PharmaceuticalsLeukemiaChronic-Phase Chronic Myeloid Leukemia (CP-CML), second lineOral
brigatinibAriad PharmaceuticalsLungALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinibOral
brigatinibAriad PharmaceuticalsLungALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitorOral
Braftovi + Mektoviencorafenib + binimetinibArray BioPharmaMelanomaBRAF-mutant melanomaOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm
encorafenibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer in combination with binimetinib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
binimetinibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer, in combination with encorafenib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
binimetinibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with encorafenibOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
zolbetuximab (IMAB362)Astellas PharmaGastrointestinalGastroesophageal adenocarcinomaIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
XospatagilteritinibAstellas PharmaLeukemiaAcute myeloid leukemiaOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627045.htm
enfortumab vetodinAstellas PharmaGenitourinaryUrothelial cancerIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
ASG-16C3FAstellas PharmaGenitourinaryRenal cell carcinomaIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
selumetinibArray BioPharmaEndocrineDifferentiated Thyroid CancerOral
savolitinibAstraZenecaGenitourinaryPapillary renal cell carcinomahttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungBrain metastases in advanced EGRFm NSCLCOral
TagrissoosimertinibAstraZenecaLungAdjuvant EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
naquotinib (ASP8273)Astellas PharmaLungNon-small cell lung cancerOral
TagrissoosimertinibAstraZenecaLungfirst line advanced EGRFm NSCLCOral
LynparzaolaparibAstraZenecaGenitourinaryProstate cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGynecologyFirst line BRCAm ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA adjuvant breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA metastatic breast cancerOral
LynparzaolaparibAstraZenecaGastrointestinalPancreatic cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
Lumoxitimoxetumomab pasudotoxAstraZenecaLeukemiaHairy cell leukaemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm620473.htm
dusigitumab (MEDI-573)AstraZenecaBreastMetastatic breast cancer
durvalumab + tremelimumabAstraZenecaGastrointestinalGastric cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalMetastatic pancreatic ductal carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalHepatocellular carcinomaIntravenoushttps://www.astrazeneca.com/our-science/pipeline.html
durvalumab + tremelimumabAstraZenecaLung3rd-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGenitourinary1st-line bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck2nd-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck1st-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaHead and NeckSquamous cell carcinoma of the head and neckIntravenous
ImfinzidurvalumabAstraZenecaLungStage III NSCLCIntravenous
ImfinzidurvalumabAstraZenecaLung1st-line NSCLCIntravenous
ImfinzidurvalumabAstraZenecaGenitourinaryAdvanced bladder cancerIntravenous
ImfinzidurvalumabAstraZenecaGenitourinaryTreatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemo or who have disease progression within 12 mo. of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenous
cediranibAstraZenecaGynecologyRecurrent platinum resistant ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD6738AstraZenecaGastrointestinalGastric cancer, in combination with olaparibhttps://www.astrazeneca.com/our-focus-areas/oncology.html
capivasertibAstraZenecaBreastBreast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD1775AstraZenecaGynecologyOvarian cancer, in combination with chemotherapyhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLymphomaB-cell malignancyOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaRelapsed/refractory chronic lymphocytic leukemia and high riskOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
NimoralnimorazoleAzanta A/SHead and NeckFirst-line platinum-resistent head and neck squamous cell carcinomaOral
NimoralnimorazoleAzanta A/SHead and NeckHead and neck squamous cell carcinoma, second line re-irradiation, accelerated or conventinal chemo-radiation therapy (CRT)Oral
NimoralnimorazoleAzanta A/SHead and NeckHead and neck squamous cell carcinoma, first line accelerated chemo-radiation therapy (CRT)Oral
StivargaregorafenibBayerGastrointestinaladjuvant therapy for colorectal cancerOral
Radium-223 dichlorideBayerBreastbone metastasis in breast cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
Radium-223 dichlorideBayerGenitourinaryCastration-resistant prostate cancerIntravenous
darolutamideBayerGenitourinaryCastration-resistant prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryhormone sensitive prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenous
GiotrifafatinibBoehringer IngelheimLungStage IIIB or IV adenocarcinoma of the lung harbouring an epidermal growth factor receptor (EGFR) activating mutationOral
GiotrifafatinibBoehringer IngelheimLungFirst‑line treatment of patients with common epidermal growth factor receptor (EGFR) mutations (del19/L858R) and advanced adenocarcinoma of the lungOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592558.htm
AliqopacopanlisibBayerLymphomaNon Hodgkin LymphomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomarelapsed follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm576098.htm
BI 1361849Boehringer IngelheimLungNon-small cell lung cancer
anetumab ravtansine BayerLungMalignant pleural mesotheliomaIntravenous
xentuzumabBoehringer IngelheimBreastMetastatic breast cancerhttps://www.inoncology.com/our-compounds
xentuzumabBoehringer IngelheimGenitourinaryCastration-resistant prostate cancerhttps://www.inoncology.com/our-compounds
VargatefnintedanibBoehringer IngelheimOtherUnresectable malignant pleural mesothelioma, in combination with pemetrexed/cisplatinOral
VargatefnintedanibBoehringer IngelheimLungAdvanced non‑small cell lung cancer Oralhttps://www.inoncology.com/our-compounds
VargatefnintedanibBoehringer IngelheimLungStage IIIB/IV or recurrent non‑small cell lung cancer (NSCLC) after failure of first‑line chemotherapy, in combination with docetaxelOral
BI 836858Boehringer IngelheimLeukemiaAcute Myeloid Leukemia
OpdivonivolumabBristol-Myers SquibbLymphomaFor patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (Adcetris)Intravenous
AG-221CelgeneLeukemiaAcute myeloid leukemia
BI 836858Boehringer IngelheimLeukemiaMyelodysplastic syndrome
BI 836826Boehringer IngelheimLymphomaNon-Hodgkin lymphoma
BI 836826Boehringer IngelheimLeukemiaChronic lymphocytic leukemia
GiotrifafatinibBoehringer IngelheimLungSquamous Non-Small Cell Lung Cancer Oralhttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimLungNon-small cell lung cancer after failure of erlotinib or gefitinibOral
GiotrifafatinibBoehringer IngelheimLungPatients with non-small cell lung cancer (NSCLC) who had failed at least one line of chemotherapy and erlotinib or gefitinib treatmentOral
GiotrifafatinibBoehringer IngelheimHead and NeckRecurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum‑based therapyOralhttps://www.inoncology.com/our-compounds
RevlimidlenalidomideCelgeneMyelomaRelapsed/refractory multiple myelomaOral
RevlimidlenalidomideCelgeneMyelomaMaintenance therapy for patients with multiple myeloma following autologous stem cell transplantOral
GiotrifafatinibBoehringer IngelheimLungAdvanced NSCLC Harbouring HER2 Mutations, Previously Treated With ChemotherapyOral
GiotrifafatinibBoehringer IngelheimGenitourinaryadvanced platinum-refractory urothelial cancerOralhttps://www.inoncology.com/our-compounds
OpdivonivolumabBristol-Myers SquibbGenitourinaryLocally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapyIntravenous
OpdivonivolumabBristol-Myers SquibbGastrointestinalmismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm
OpdivonivolumabBristol-Myers SquibbGastrointestinalhepatocellular carcinoma (HCC) in patients, previously treated with sorafenibIntravenous
ThalomidthalidomideCelgeneMyelomaNewly diagnosed multiple myelomaOralhttps://www.celgene.com/research-development/
IstodaxromidepsinCelgeneLymphomaFirst-line peripheral T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
IstodaxromidepsinCelgeneLymphomaCutaneous T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
Abraxanenab-paclitaxelCelgeneGastrointestinalPancreatic cancer, first-lineIntravenous
CC-486CelgeneOtherLower-risk myelodysplastic syndromeOralhttps://www.celgene.com/research-development/
Abraxanenab-paclitaxelCelgeneLungAdvanced non-small cell lung cancer (first-line)Intravenous
Abraxanenab-paclitaxelCelgeneBreastFirst-line metastatic triple-negative breast cancerIntravenous
oral azacitidine (CC-486)CelgeneOtherMyelodysplastic syndromeOral
oral azacitidine (CC-486)CelgeneLungAdvanced non-small cell lung cancerOral
oral azacitidine (CC-486)CelgeneBreastMetastatic breast cancerOral
Abraxanenab-paclitaxelCelgeneGastrointestinalAdjuvant therapy for pancreatic cancerIntravenous
marizomibCelgeneNeurologicalGlioblastoma multiformehttps://www.celgene.com/research-development/
luspaterceptCelgeneOtherMyleodysplastic syndromeSubcutaneoushttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneOtherMyelodysplastic syndrome - deletion 5qOral
RevlimidlenalidomideCelgeneLymphomaFirst-line diffuse large B-cell lymphoma (ABC-subtype)Oralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaRelapsed/refractory indolent lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaFirst-line follicular lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaMantle cell lymphoma (relapsed/refractory)Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
IdhfaenasidenibCelgeneLeukemiarelapsed or refractory acute myeloid leukemia Oralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm
durvalumabCelgeneLeukemiaAcute myeloid leukemia (AML)Intravenous
durvalumabCelgeneOtherMyleodysplastic syndromeIntravenous
CC-486CelgeneLeukemiaPost-induction acute myeloid leukemia maintenanceIntravenoushttps://www.celgene.com/research-development/
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (20-30% blasts)Intravenous
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (>30% blasts)Intravenous
Vidazaazacitidine for injectionCelgeneOtherMyelodysplastic syndromesIntravenous
RubracarucaparibClovis OncologyGynecologyDeleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapiesOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
MORAb-004EisaiMelanomaMelanomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalHepatocellular carcinomaOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm
LenvimalenvatinibEisaiGastrointestinalBiliary tract cancerOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryFirst-line renal cell carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryin combination with everolimus, for advanced renal cell carcinoma following one prior anti-angiogenic therapyOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
farletuzumabEisaiGynecologyPlatinum-sensitive ovarian cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LartruvaolaratumabEli LillySarcomaSoft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriateIntravenous
HalaveneribulinEisaiGenitourinaryUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Intravenous https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm
HalaveneribulinEisaiSarcomaAdvanced soft tissue sarcomaIntravenous
HalaveneribulinEisaiBreastTriple negative Breast cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
amatuximabEisaiLungMesotheliomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
CyramzaramucirumabEli LillyGastrointestinalMetastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimenIntravenoushttp://wayback.archive-it.org/7993/20170111231635/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
CyramzaramucirumabEli LillyGastrointestinalGastric cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
CyramzaramucirumabEli LillyGastrointestinalHepatocellular carcinoma, second-line treatment Intravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalSecond-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma, in combination with paclitaxelIntravenous
CyramzaramucirumabEli LillyGastrointestinalAdvanced gastric or gastroesophageal junction adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidineIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalMetastatic gastric or gastroesophageal junction adenocarcinomaIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxelIntravenoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer, EGFR mutation, previously untreatedIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGenitourinaryUrothelial carcinomaIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungStage IV non-small cell lung cancer following disease progression after prior platinum-based chemotherapy, in combination with weekly docetaxelIntravenous
ralimetinibEli LillyGynecologyOvarian cancerOral
prexasertibEli LillyLungSmall cell lung cancer Intravenoushttp://lillyoncologypipeline.com/cancer-type
necitumumabEli LillyLungSquamous non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
merestinibEli LillyGastrointestinalFirst-line advanced or metastatic biliary tract cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
LY3023414Eli LillyLungNon-small cell lung cancerOral
LY3023414Eli LillyGenitourinaryProstate cancerOralhttp://lillyoncologypipeline.com/cancer-type
galunisertibEli LillyGastrointestinalHepatocellular CarcinomaOral
emibetuzumabEli LillyLungNon-small cell lung cancerIntravenous
VerzenioabemaciclibEli LillyGastrointestinalPancreatic cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
VerzenioabemaciclibEli LillyLungStage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapyOral
VerzenioabemaciclibEli LillyLungSquamous non-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
VerzenioabemaciclibEli LillyBreastPostmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer, with anastrozole or fulvestrantOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
VerzenioabemaciclibEli LillyBreastwith Trastuzumab for Hormone-Receptor-Positive, HER2-Positive Locally Advanced or Metastatic Breast CancerOral
VerzenioabemaciclibEli LillyNeurologicalPatients with brain metastases secondary to hormone-receptor-positive breast cancer, non-small cell lung cancer, or melanomaOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
tepotinibEMD SeronoGastrointestinalHepatocellular cancerOralhttps://www.emdserono.com/us-en/research.html
tepotinibEMD SeronoLungNon-small cell lung cancerOralhttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGastrointestinalGastric cancer, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGastrointestinalThird line gastric cancerIntravenous
CometriqcabozantinibExelixisLungNon-small cell lung cancer: metastases to the brainOral
BavencioavelumabEMD SeronoGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGynecologyOvarian cancer, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoHead and NeckLocally advanced head and neckIntravenoushttps://www.emdserono.com/us-en/research.html
avelumabEMD SeronoOtherMerkel cell carcinomaIntravenous
BavencioavelumabEMD SeronoLungNon-small cell lung cancer, first lineIntravenous
CometriqcabozantinibExelixisGenitourinaryFor treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapyOral
BavencioavelumabEMD SeronoLungNon-small cell lung cancerIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGenitourinaryRenal cell carcinoma, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
CometriqcabozantinibExelixisGastrointestinalColorectal cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
BavencioavelumabEMD SeronoGenitourinaryUrothelial cancer. first lineIntravenoushttps://www.emdserono.com/us-en/research.html
avelumabEMD SeronoGenitourinaryUrothelial cancer 1L2Intravenous
AvastinbevacizumabGenentechLungAdjuvant non-small cell lung cancerIntravenous
AvastinbevacizumabGenentechBreastAdjuvant breast cancer, HER2-negativeIntravenous
AvastinbevacizumabGenentechGynecologyFirst-line metastatic ovarian cancerIntravenous
AvastinbevacizumabGenentechBreastAdjuvant breast cancer, HER2-postiveIntravenous
AvastinbevacizumabGenentechEndocrineHigh-risk carcinoidIntravenous
BavencioavelumabEMD SeronoGenitourinaryLocally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Intravenous
CometriqcabozantinibExelixisGastrointestinalHepatocellular cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaSoft tissue sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastBreast cancer patients with brain metastasesOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastMetastatic, hormone-receptor positive breast cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisLungNon-small cell lung cancer with molecular alterations in RET, ROS1, MET, AXL, or NTRK1Oral
CometriqcabozantinibExelixisLungNon-small cell lung cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyEndometrial cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaHigh grade uterine sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaRelapsed osteosarcoma or Ewing sarcomasOralhttps://www.exelixis.com/cabozantinib-development-program/
SERD (GDC-0810)GenentechBreastER+ HER2-ngeative breast cancerOral
CometriqcabozantinibExelixisEndocrineDifferentiated thyroid cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGenitourinaryRenal cell cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
ZelborafvemurafenibGenentechEndocrinePapillary thyroid cancer, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
CometriqcabozantinibExelixisGenitourinaryBladder cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastTriple negative breast cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic pancreatic cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeuroendocrine and carcinoid tumorsOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic gastrointestinal stromal tumorOralhttps://www.exelixis.com/cabozantinib-development-program/
ErivedgevismodegibGenentechOtherOperable basal cell carcinomaOralhttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast1st line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast3rd line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
RITUXAN HYCELArituximab and hyaluronidase humanGenentechLeukemiafollicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemiaIntravenous
polatuzumab vedotinGenentechLymphomaNon-Hodgkin's lymphoma and diffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastEarly HER2-positive breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreast2nd line HER2-negative breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLeukemiaFront-line chronic lymphocytic leukemiaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaDiffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalGastric cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechBreastTriple-negative breast cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalProstate cancerOralhttps://www.gene.com/medical-professionals/pipeline
AvastinbevacizumabGenentechNeurologicalFirst-line glioblastoma multiformeIntravenous
AvastinbevacizumabGenentechGynecologyRelapsed platinum-sensitive ovarian cancer Intravenous
TecentriqatezolizumabGenentechGenitourinaryFor locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
tirabrutinibGilead SciencesLymphomaB-cell malignanciesOralhttp://www.gilead.com/research/pipeline
ZydeligidelalisibGilead SciencesLeukemiaRelapsed refractory chronic lymphocytic leukemia (CLL)Oral
entospletinibGilead SciencesLeukemiaAcute Myeloid LeukemiaOral
entospletinibGilead SciencesLeukemiaHematological MalignanciesOralhttp://www.gilead.com/research/pipeline
andecaliximabGilead SciencesGastrointestinalGastric CancerSubcutaneoushttp://www.gilead.com/research/pipeline
VenclextavenetoclaxHoffmann-La RocheLeukemiaFrontline chronic lymphocytic leukemia, in combination with GazyvaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaRealpsed/refractory chronic lymphocytic leukemia, in combination with rituximabOral
VenclextavenetoclaxHoffmann-La RocheLeukemiamyelodysplastic syndromes, first-line treatment, in combination with azacitidineOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheMyelomaRelapsed or refractory multiple myelomaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaFront-line diffuse large B-cell lymphomaOral
VenclextavenetoclaxHoffmann-La RocheLymphomaRelapsed/refractory follicular lymphoma, in combination with rituximabOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatmentOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626499.htm
ZelborafvemurafenibHoffmann-La RocheMelanomaAdjuvant melanoma, BRAF mutation positiveOral
vanucizumabHoffmann-La RocheGastrointestinalColorectal cancer
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatment, in combination with PerjetaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastSecond line HER2-positive metastatic breast cancer, in combination with TecentriqIntravenous
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastThird line HER2-positive metastatic breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive breast cancer, neoadjuvant treatmentOral
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive metastatic breast cancerOral
RituxanrituximabHoffmann-La RocheLeukemiaChronic lymphocytic leukemiaSubcutaneous
polatuzumab vedotinHoffmann-La RocheLeukemiaFirst line Diffuse Large B-cell LymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
PerjetapertuzumabHoffmann-La RocheGastrointestinalAdvanced HER2-positive gastric cancerIntravenous
PerjetapertuzumabHoffmann-La RocheBreastEarly HER2-positive breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabHoffmann-La RocheLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenous
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, new-adjuvant treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
idasanutlinHoffmann-La RocheLeukemiaAcute myeloid leukemiaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
codrituzumabHoffmann-La RocheGastrointestinalMetastatic liver cancerhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumab + vemurafenibHoffmann-La RocheMelanomaBRAFv600 mutation-positive advanced melanoma, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheGastrointestinalThird-line advanced or metastatic colorectal cancer, in combination with TecentriqOral
CotelliccobimetinibHoffmann-La RocheBreastFirst line metastatic triple negative breast cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
AvastinbevacizumabHoffmann-La RocheGynecologyRelapsed platinum-sensitive ovarian cancerIntravenous
TecentriqatezolizumabHoffmann-La RocheGynecologyOvarian cancer, front-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinarySecond-line urothelial bladder cancerIntravenous
TecentriqatezolizumabHoffmann-La RocheGenitourinary1st-line cis-ineligible and 2nd-line metastatic urothelial bladder cancerIntravenous
DarzalexdaratumumabJanssenMyelomaDouble refractory multiple myelomaIntravenous
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patientsIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungSecond-line non-small cell lung cancerIntravenous
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell cancer, in combination with AvastinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without AvastinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungMetastatic non-small cell lung cancer whose disease progressed during or following platinum-containing chemotherapyIntravenous
TecentriqatezolizumabHoffmann-La RocheLungNon-small cell lung cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line squamous non-small cell lung cancer, combination regimen with chemotherapyIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
imetelstatJanssenOtherRelapsed/refractory myelofibrosisIntravenous
TecentriqatezolizumabHoffmann-La RocheGenitourinaryMuscle-invasive bladder cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryFirst-line metastatic urothelial carcinomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapyIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexedIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst line extensive-stage small cell lung cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastMetastatic triple-negative breast cancer, first-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
KeytrudapembrolizumabMerckGenitourinaryBladder cancerIntravenous
AlecensaalectinibHoffmann-La RocheLungALK+ metastatic non-small cell lung cancer, first lineOral
SomatulinelanreotideIpsen PharmaGastrointestinalUnresectable, well or moderately differentiated, locally, advanced or metastatic gastroenteropancreatic neuroendocrine tumorsSubcutaneous
YondelistrabectedinJanssenGynecologyRelapsed ovarian cancerIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia, in combination with obinutuzumabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia (young and fit), in combinaction with rituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaTreatment naive patients with mantle cell lymphoma, in combination with Bendamustine and RituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaNewly diagnosed non-germinal centre B-cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaMarginal zone lymphoma in patients who have received at least one prior therapyOral
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with bortezomib, melphalan and prednisoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with lenalidomide and low-dose dexamethasoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-eligible patients, in combination with velcade, thalidomide and dexamethasomeIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
apalutamide + abiraterone acetateJanssenGenitourinaryMetastatic castration-resistant chemotherapy-naïve prostate cancerOral
apalutamideJanssenGenitourinaryNon-metastatic, castration-resistant prostate cancerOral
apalutamideJanssenGenitourinaryMetastatic hormone-sensitive prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryLocalized prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
ZytigaabirateroneJanssenGenitourinaryNewly Diagnosed Hormone Naïve Metastatic Prostate Cancer Oralhttp://www.janssen.com/research-and-development/product-pipeline
KisqaliribociclibNovartisBreastFor the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancerOral
Vyxeosliposome-encapsulated combination of daunorubicin and cytarabine Jazz PharmaceuticalLeukemianewly diagnosed high risk AMLIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm
KeytrudapembrolizumabMerckGastrointestinalEsophogeal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalrecurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
KeytrudapembrolizumabMerckGastrointestinalColorectal CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalLiver cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyOvarian CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckBreastBreast cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryRenal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryProstate cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckNasopharyngeal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckRecurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm
KeytrudapembrolizumabMerckMyelomaMultiple myelomaIntravenous
KeytrudapembrolizumabMerckLymphomaPrimary mediastinal primary B-cell lymphomaIntravenous
KymriahtisagenlecleucelNovartisLeukemiaacute lymphoblastic leukemia Intravenous
OdomzosonidegibNovartisOtherlocally advanced basal cell carcinomaOralhttp://wayback.archive-it.org/7993/20170111231633/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
KisqaliribociclibNovartisBreastBreast cancer, in combination with Everolimus + Exemestane or in combination with fulvestrantOral
FarydakpanobinostatNovartisMyelomaMultiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agentOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
XtandienzalutamidePfizerBreastTriple negative breast cancerOral
ArzerraofatumumabNovartisLeukemiaFor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
LCL161NovartisLeukemiaLeukemia
LCL161NovartisMyelomaMultiple myeloma
EGF816NovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
capmatinibNovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
buparlisibNovartisGastrointestinalGastroesophageal junction cancerOral
buparlisibNovartisHead and NeckGlioblastoma multiformeOral
buparlisibNovartisHead and NeckHead and neck cancerOral
buparlisibNovartisBreastBreast cancerOral
alpelisibNovartisLungNon-small cell lung cancerOral
alpelisibNovartisHead and NeckHead and neck squamous cell carcinomaOral
alpelisibNovartisBreastBreast Cancer (HR+, HER2-)Oralhttps://www.novartis.com/our-company/novartis-oncology
talazoparibPfizerBreastGermline BRCA-mutated metastatic breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
SutentsunitinibPfizerGenitourinaryadjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.htm
IbrancepalbociclibPfizerHead and NeckSquamous cell carcinoma of the head and neckOral
IbrancepalbociclibPfizerBreastHigh-risk early breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastEarly breast cancer in adjuvant settingOralhttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastFor the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in combination with fulvestrantOral
LorbrenalorlatinibPfizerLungALK non-small cell lung cancer, first line and second lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm
inotuzumab ozogamicinPfizerLeukemiaAcute lymphocytic leukemiaIntravenous
glasdegibPfizerLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.pfizer.com/science/drug-product-pipeline
Mylotarggemtuzumab ozogamicinPfizerLeukemiaAcute Myeloid LeukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm
XtandienzalutamidePfizerGastrointestinalHepatocellular carcinomaOral
vadastuximab talirineSeattle GeneticsLeukemiaFrontline older acute myeloid leukemiaIntravenous
vadastuximab talirineSeattle GeneticsLeukemiaRelapsed acute myeloid leukemia pre/post allo-transplantIntravenous
vadastuximab talirineSeattle GeneticsOtherFrontline myelodysplastic syndrome, in combination with hypomethylating agentsIntravenous
XtandienzalutamidePfizerGenitourinaryNon-metastatic castration-resistant prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm613543.htm
XtandienzalutamidePfizerGenitourinaryProstate cancer in patients with non-metastatic biochemical recurrenceOral
XtandienzalutamidePfizerGenitourinaryMetastatic hormone sensitive prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
VizimprodacomitinibPfizerLungFirst-line EGFR-mutant non-small cell lung cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
XalkoricrizotinibPfizerLungROS1-positive metastatic non-small cell lung cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
BosulifbosutinibPfizerLeukemiaChronic myelogenous leukemia, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589856.htm
InlytaaxitinibPfizerGenitourinaryRenal cell carcinoma, adjuvant therapy in combination with pembroliumab Oralhttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerMelanomaMetastatic Merkel Cell CarcinomaIntravenous
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, second lineIntravenous
BavencioavelumabPfizerGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerHead and NeckLocally Advanced Squamous Cell Carcinoma of the Head and NeckIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryRenal cell carcinoma adjuvant, in combination with Keytruda (pembrolizumab)Intravenous
BavencioavelumabPfizerLungNon small cell lung cancer, second lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyOvarian cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, third lineIntravenous
NerlynxneratinibPuma Biotechnology Inc.Breastfor the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm
LibtayocemiplimabSanofiSkinAdvanced cutaneous squamous cell carcinomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm622251.htm
LibtayocemiplimabSanofiSkinAdvanced basal cell carcinomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
LibtayocemiplimabSanofiLungNSCLC, first lineIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
isatuximabSanofiLeukemiaAcute Lymphoblastic LeukemiaIntravenous
isatuximabSanofiMeylomaRelapsed refractory multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
tisotumab vetodinSeattle GeneticsGenitourinaryCervical cancerhttp://www.seattlegenetics.com/pipeline
denintuzumab mafodotinSeattle GeneticsLymphomaRelapsed diffuse large B-cell lymphoma (rituximab + chemotherapy +/− SGN-CD19A)Intravenous
denintuzumab mafodotinSeattle GeneticsLymphomaFrontline diffuse large B-cell lymphoma, in combination with chemotherapy) (planned)Intravenous
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline Hodgkin lymphoma, in combination with chemotherapyIntravenous
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline mature T-cell lymphomasIntravenoushttp://www.seattlegenetics.com/pipeline/brentuximab-vedotin
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaCD30-expressing cutaneous T-cell lymphomaIntravenous
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline Hodgkin lymphoma in patients 60+Intravenous
Adcetrisbrentuximab VedotinSeattle GeneticsLymphomaRelapsed CD30-expressing diffuse large B-cell lymphoma (rituximab + bendamustine +/− brentuximab vedotinIntravenous
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaSecond-line Hodgkin lymphoma, in combination with nivolumabIntravenous
BavencioavelumabEMD SeronoOtherMerkel cell carcinoma, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaRelapsed non-Hodgkin lymphomaIntravenoushttp://www.seattlegenetics.com/pipeline
BeleodaqbelinostatSpectrumLymphomaRelapsed or refractory peripheral T-cell lymphomaIntravenoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm
sapanisertibTakedaBreastBreast cancerOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
sapanisertib (TAK-228)TakedaGynecologyEndrometrial CancerOral
sapanisertib (TAK-228)TakedaGenitourinaryRenal CancerOral
IclusigponatinibTakedaLeukemiaImatinib resistant chronic phase Chronic myelogenous leukemia (CML)Oral
IclusigponatinibTakedaLeukemiaSecond-line chronic phase Chronic myelogenous leukemia (CML)Oral
IclusigponatinibTakedaLeukemiaPh+Acute lymphoblastic leukemia (ALL)Oralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
pevonedistatTakedaLeukemiaChronic Myeloid LeukemiaIntravenous
NinlaroixazomibTakedaMyelomaAmyloidosisOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance non SCTOral
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance post SCTOral
NinlaroixazomibTakedaMyelomaNewly diagnosed multiple myelomaOral
AlunbrigbrigatinibTakedaLymphomaFollicular lymphomaOral
Adcetrisbrentuximab vedotinTakedaLymphomaHodgkin LymphomaIntravenous
Adcetrisbrentuximab vedotinTakedaLymphomaMature T-cell lymphomaIntravenous
AdcetrisbrentuximabTakedaLymphomaHL post TransplantIntravenous
Adcetrisbrentuximab vedotinTakedaLymphomaCutaneous T-Cell LymphomaIntravenous
ZejulaniraparibTesaro, Inc.Gynecologymaintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm
UnituxindinutuximabUnited TherapeuticsNeurologicalHigh-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm437480.htm
GiotrifafatinibBoehringer IngelheimLungin Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the LungOral
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaindolent NHLIntravenoushttp://www.gilead.com/research/pipeline
YescartaAxicabtagene ciloleucel Kite PharmaceuticalsLymphomarelapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm581296.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm
CabometyxcabozantinibIpsen PharmaGastrointestinalHepatocellular carcinoma, second lineOralhttps://www.ipsen.com/research-development/pipeline/
E7777EisaiLymphomaPeripheral T-cell and Cutaneous T-Cell LymphomaIntravenous
VerzenioabemaciclibEli LillyBreastHigh-Risk, Node-Positive, Early-Stage, Hormone-Receptor-Positive, HER 2-Negative Breast Cancer, adjuvant therapyOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
VerzenioabemaciclibEli LillyBreastPreviously Treated Hormone-Receptor-Positive, HER2-Negative, Metastatic Breast Cancer, with tamoxifenOral
XtandienzalutamidePfizerGenitourinaryNon-metastatic hormone sensitive, high risk, prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
VerzenioabemaciclibEli LillyBreastin combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm578081.htm
LibtayocemiplimabSanofiGynecologyCervical cancerIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaprimary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
SpryceldasatinibBristol-Myers SquibbLeukemiapediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phaseOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584725.htm
BlincytoblinatumomabAmgenLeukemiaRelapsed/Refractory (R/R) Aggressive B-Cell NHLIntravenoushttp://www.amgenpipeline.com/pipeline/
IclusigponatinibTakedaLeukemiaChronic phase Chronic Myeloid Leukemia (CML)https://www.takeda.com/what-we-do/research-and-development/our-pipeline/
AlunbrigbrigatinibTakedaLungALK+ Non-small cell lung cancerOral
AdcetrisbrentuximabTakedaLymphomaAnaplastic Large Cell LymphomaOral
NinlaroixazomibTakedaMyelomaMultiple myeloma, front lineOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
VectibixpanitumumabTakedaGastrointestinalColorectal CancerIntravenous
pevonedistatTakedaLeukemiaLow-Blast Acute Myelogenous LeukemiaIntravenoushttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-117TakedaGynecologyEndrometrial CancerOral
TAK-117TakedaGenitourinaryRenal CancerOral
TAK-659TakedaLymphomaDiffuse large B-cell lymphomaOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-659TakedaLeukemiaAcute Myelogenous LeukemiaOral
KTE-C19Gilead SciencesLymphomaMCLIntravenoushttp://www.gilead.com/research/pipeline
CalquenceacalabrutinibAstraZenecaLeukemiaMantle cell lymphoma, after at least one prior therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm
asciminib (ABL001)NovartisLeukemiaChronic Myeloid LeukemiaOralhttps://www.novartis.com/our-company/novartis-oncology
denintuzumab mafodotinSeattle GeneticsLymphomaDiffuse large B-cell lymphomaIntravenous
ladiratuzumab vedotin (SGN-LIV1A)Seattle GeneticsBreastBreast cancerhttp://www.seattlegenetics.com/pipeline
enfortumab vedotin Seattle GeneticsGenitourinarymetastatic urothelial cancer Intravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomapreviously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm601947.htm
OpdivonivolumabBristol-Myers SquibbMelanoma adjuvant treatment of patients with melanomaIntravenous
TecentriqatezolizumabHoffmann-La RocheBreastAdjuvant triple-negative breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
AvastinbevacizumabHoffmann-La RocheNeurologyGlioblastoma multiformeIntravenous
GazyvaobinutuzumabGenentechLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastAdjuvant HER2-positive breast cancerIntravenous
PerjetapertuzumabGenentechGastrointestinalHER2-positive gastric cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
ZelborafvemurafenibGenentechMelanomaAdjuvant metastatic melanoma, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
Lutatheralutetium Lu 177 dotatateAdvanced Accelerator Applications USA, IncOtherreceptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm594105.htm
tazemetostatEisaiLymphomaNon-Hodgkin B cell Lymphomaoral
SAR566658SanofiBreastTriple negative breast cancer
NinlaroixazomibTakedaMyelomaMultiple myeloma, relapsed/refractory, doublet regimenOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance therapy, with or without transplantOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
ZytigaabirateroneJanssenGenitourinaryin combination with prednisone for metastatic high-risk castration-sensitive prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596015.htm
VerzenioabemaciclibEli LillyBreastin combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm598404.htm
ZytigaabirateroneJanssenGenitourinaryIn combination with prednisone and androgen deprivation therapy (adt) for the treatment of patients with newly diagnosed high-risk mestastatic prostate cancer who may have received up to 3 months of prior ADTOral
talazoparibPfizerGenitourinaryMetastatic castration-resistant prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
xentuzumabBoehringer IngelheimLungNon small cell lung cancer
VargatefnintedanibBoehringer IngelheimLungin combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapyOral
Somatuline PRFlanreotideIpsen PharmaGastrointestinalgastroenteropancreatic neuroendocrine tumors (GEP-NET)Subcutaneous
Onivydeirinotecan liposomeIpsen PharmaGastrointestinalPancreatic ductal adenocarcinomab (PDAC)Intravenoushttps://www.ipsen.com/research-development/pipeline/
Onivydeirinotecan liposomeIpsen PharmaLungSmall Cell Lung cancer (SCLC), second lineIntravenoushttps://www.ipsen.com/research-development/pipeline/
Ga 68-OPS202Ipsen PharmaGastrointestinalgastroenteropancreatic neuroendocrine tumors (GEP-NET)Intravenous
SomatulinelanreotideIpsen PharmaLungNeuroendocrine Tumours of LungSubcutaneous
KeytrudapembrolizumabMerckLungSmall Cell Lung cancer (SCLC)Intravenoushttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGastrointestinalPancreatic cancerOralhttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGenitourinaryProstate cancerOralhttps://www.merck.com/research/pipeline/home.html
isatuximabSanofiLymphomaNewly diagnosed multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
TasignanilotinibNovartisLeukemiapediatric patients with newly diagnosed or resistant/intolerant Ph+ CML in chronic phaseOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm602264.htm
BlincytoblinatumomabAmgenLeukemia B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603171.htm
telisotuzumab vedotinAbbVieLungNon-small cell lung cancerIntravenoushttps://www.abbvie.com/our-science/pipeline/abbv-399.html
Imfinzi + Lynparzadurvalumab + olaparibAstraZenecaGenitourinary1st-line unresectable stage IV bladder cancer
selumetinibAstraZenecaNeurologicalpediatric neurofibromastosis type 1
tislelizumabCelgeneLungNon-small cell lung cancerIntravenoushttps://www.celgene.com/research-development/
tislelizumabCelgeneGastrointestinalHepatocellular carcinomaIntravenoushttps://www.celgene.com/research-development/
tislelizumabCelgeneGastrointestinalEsophageal squamous cell carcinomaIntravenoushttps://www.celgene.com/research-development/
Liso-cel, JCAR017CelgeneLymphomaLarge B-Cell LymphomaIntravenoushttps://www.celgene.com/research-development/
LenvimalenvatinibEisaiGynecologicalendometrial carcinomaboral https://www.eisai.com/company/business/research/pdf/epipeline.pdf
CyramzaramucirumabEli LillyGenitourinaryBladder cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/III
LartruvoolaratumabEli LillySarcomaAdvanced Soft Tissue Sarcoma, in combination with gemcitabine and docetaxelIntravenoushttp://lillyoncologypipeline.com/molecule/pdgfr-alpha-antibody/trials
pegilodecakinEli LillyGastrointestinalPancreatic cancerSubcutaneoushttp://lillyoncologypipeline.com/clinical-phase/III
prexasertibEli LillyGynecologicalPlatinum-Resistant or Refractory Recurrent Ovarian CancerIntravenoushttp://lillyoncologypipeline.com/cancer-type
pegilodecakinEli LillyLungNon-small cell lung cancerSubcutaneoushttp://lillyoncologypipeline.com/clinical-phase/II
abituzumabEMD SeronoGastrointestinalColorectal CancerOralhttps://www.emdserono.com/us-en/research.html
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumabHoffmann-La RocheMelanomaBRAF wild type metastatic melanoma, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
entrectinibGenentechLungNon-small cell lung canceroralhttps://www.gene.com/medical-professionals/pipeline
entrectinibHoffmann-La RocheLungNon-small cell lung canceroralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
tiragolumabGenentechLungNon-small cell lung cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
polatuzumab vedotinHoffmann-La RocheLymphomaFollicular lymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ImbruvicaibrutinibJanssenLymphomaPatients with mantle cell lymphoma who have received at least one prior therapyOral
CometriqcabozantinibExelixisGenitourinaryProstate cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyOvarian cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisMyelomaMultiple myeloma, in combination with carfilzomibOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisHead and NeckSquamous cell carcinoma of the head and neckOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeurofibromasOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalpediatriac gliomaOralhttps://www.exelixis.com/cabozantinib-development-program/
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaDiffuse large B-cell lymphomaIntravenoushttp://www.gilead.com/research/pipeline
AlecensaalectinibHoffmann-La RocheLungALK+ non-small cell lung cancer, adjuvantOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first line in combination with nivolumabOralhttps://www.ipsen.com/research-development/pipeline/
DarzalexdaratumumabJanssenMyelomaSmoldering multiple myelomaIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaRelapsed/refractory multiple myeloma, in combination with pomalidomideIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
KeytrudapembrolizumabMerckSkinCutaneous squamous cell carcinomaIntravenoushttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckGynecologicalEndometrial canceroralhttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckGastrointestinalBiliary tract canceroralhttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckLungNon-small cell lung canceroralhttps://www.merck.com/research/pipeline/home.html
Cavatakcoxsackievirus, CVA21MerckMelanomaMelanomaIntratumoralhttps://www.merck.com/research/pipeline/home.html
IlariscanakinumabNovartisLungNon-small cell lung cancerSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
IlariscanakinumabNovartisLungNon-small cell lung cancer, adjuvant treatmentSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
ArzerraofatumumabNovartisLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLeukemiaChronic lymphocytic leukemiaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLymphomaRelapsed/refractory diffuse large B-cell lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartislymphomaRelapsed/refractory follicular lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, adjuvantOralhttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, pre-menopausal womenOralhttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
RydaptmidostaurinNovartisLeukemiaAcute myeloid leukemia, FLT3 wild typeOralhttps://www.novartis.com/our-company/novartis-oncology
BavencioavelumabPfizerSkinMerkel Cell Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastHER-2 breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
LibtayocemiplimabSanofiLungNSCLC, second lineIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
isatuximab + cemiplimabSanofiMeylomaRelapsed refractory multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaHodgkin lymphomaIntravenoushttp://www.seattlegenetics.com/pipeline
tucatinibSeattle GeneticsBreastBreast cancerhttp://www.seattlegenetics.com/pipeline
TAK-931TakedaGastrointestinalMetastatic colorectal cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-931TakedaLungNon-small cell lung cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
relugolixTakedaGenitourinaryprostate cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
Tafinlar + Mekinistdabrafenib + trametinibEndocrineanaplastic thyroid cancerhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606708.htm
KeytrudapembrolizumabMerckGynecologicalrecurrent or metastatic cervical cancerintravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm
AvastinbevacizumabGenentechGynecologyepithelial ovarian, fallopian tube, or primary peritoneal cancer intravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm
TibsovoivosidenibAngios PharmaceuticalsLeukemiaacute myeloid leukemiaoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm
Azedraiobenguane I 131 Progenics Pharmaceuticalspheochromocytoma or paraganglioma (PPGL) intravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615157.htm
OpdivonivolumabBristol-Myers SquibbLungmetastatic small cell lung cancerintravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617370.htm
CopiktraduvelisibVerastem IncLeukemiachronic lymphocytic leukemiaoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
Talzenna talazoparib PfizerBreastlocally advanced or metastatic breast canceroralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm
KeytrudapembrolizumabMerckLungmetastatic squamous non-Small Cell Lung cancer, first lineIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625705.htm
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomasystemic anaplastic large cell lymphoma (sALCL) or CD30-expressing periperal T-cell lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
VitrakvilarotrectinibBayerNTRK gene fusion solid tumoursoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626720.htm